阿培利司联合来曲唑在 CDK4/6 抑制剂治疗后对 PIK3CA 突变的 HR+/HER2-晚期乳腺癌有疗效。
Alpelisib Plus Letrozole Shows Promise After CDK 4/6 Inhibitor Therapy in PIK3CA-Mutated HR+/HER2- Advanced Breast Cancer.
出版信息
Oncologist. 2021 Feb;26 Suppl 2(Suppl 2):S15-S16. doi: 10.1002/onco.13662. Epub 2021 Jan 5.
Abstract
Treatment with alpelisib and letrozole appears to be effective in patients with HR‐positive, HER2‐negative, ‐mutated advanced breast cancer previously treated with a CDK 4/6 inhibitor, according to updated findings from the phase II BYLieve trial.
摘要
根据 II 期 BYLieve 试验的更新结果，阿培利司联合来曲唑治疗先前接受 CDK4/6 抑制剂治疗的 HR 阳性、HER2 阴性、突变型晚期乳腺癌患者似乎有效。
相似文献
1
Alpelisib Plus Letrozole Shows Promise After CDK 4/6 Inhibitor Therapy in PIK3CA-Mutated HR+/HER2- Advanced Breast Cancer.阿培利司联合来曲唑在 CDK4/6 抑制剂治疗后对 PIK3CA 突变的 HR+/HER2-晚期乳腺癌有疗效。
Oncologist. 2021 Feb;26 Suppl 2(Suppl 2):S15-S16. doi: 10.1002/onco.13662. Epub 2021 Jan 5.
2
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.阿培利司联合氟维司群治疗 CDK4/6 抑制剂治疗后 PI3KCA 突变、激素受体阳性的晚期乳腺癌（BYLieve）：一项多中心、开放标签、非对照、2 期研究的一个队列。
Lancet Oncol. 2021 Apr;22(4):489-498. doi: 10.1016/S1470-2045(21)00034-6.
3
Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer.阿培利司联合氟维司群对比 HR+/HER2-、PIK3CA 突变型乳腺癌患者真实世界标准治疗的疗效。
Oncologist. 2021 Jul;26(7):e1133-e1142. doi: 10.1002/onco.13804. Epub 2021 May 13.
4
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.哌柏西利联合来曲唑与来曲唑单药一线治疗雌激素受体阳性、HER2 阴性、晚期乳腺癌（PALOMA-1/TRIO-18）的随机 2 期研究。
Lancet Oncol. 2015 Jan;16(1):25-35. doi: 10.1016/S1470-2045(14)71159-3. Epub 2014 Dec 16.
5
Alpelisib for -Mutated, Hormone Receptor-Positive Advanced Breast Cancer.阿培利司治疗 - 突变型、激素受体阳性晚期乳腺癌。
N Engl J Med. 2019 May 16;380(20):1929-1940. doi: 10.1056/NEJMoa1813904.
6
Potential for Long-Term Disease Control with Alpelisib Plus Fulvestrant Spans Patient Subgroups in HR+ PIK3CA-Mutated Advanced Breast Cancer.阿培利司联合氟维司群治疗 HR+/PIK3CA 突变型晚期乳腺癌具有长期疾病控制潜力，涵盖了不同亚组患者。
Oncologist. 2021 Jul;26 Suppl 3(Suppl 3):S11-S12. doi: 10.1002/onco.13873. Epub 2021 Jun 26.
7
A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB).一项新辅助来曲唑联合阿培利司治疗激素受体阳性、人表皮生长因子受体 2 阴性乳腺癌的 II 期随机研究（NEO-ORB）。
Clin Cancer Res. 2019 May 15;25(10):2975-2987. doi: 10.1158/1078-0432.CCR-18-3160. Epub 2019 Feb 5.
8
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1.阿培利司联合氟维司群治疗激素受体阳性、人表皮生长因子受体 2 阴性、PIK3CA 突变的晚期乳腺癌：SOLAR-1 的最终总生存结果。
Ann Oncol. 2021 Feb;32(2):208-217. doi: 10.1016/j.annonc.2020.11.011. Epub 2020 Nov 25.
9
Alpelisib Plus Fulvestrant or Letrozole Demonstrates Sustained Benefits Across Subgroups of Patients with PIK3CA-Mutated HR+/HER2- Advanced Breast Cancer.阿培利司联合氟维司群或来曲唑治疗 PIK3CA 突变的 HR+/HER2- 晚期乳腺癌患者具有持续获益，且各亚组获益一致。
Oncologist. 2022 Mar 28;27(Suppl 1):S13-S14. doi: 10.1093/oncolo/oyac011.
10
A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.一项关于PI3Kα特异性抑制剂阿哌利西（BYL719）联合来曲唑治疗雌激素受体阳性/人表皮生长因子受体2阴性转移性乳腺癌的Ib期研究。
Clin Cancer Res. 2017 Jan 1;23(1):26-34. doi: 10.1158/1078-0432.CCR-16-0134. Epub 2016 Apr 28.
Zotero 插件